Streetbeat News

FEMY

Femasys Inc.

https://www.femasys.com

Industry

Medical - Instruments & Supplies

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Open

0.99

Mkt cap

22M

Volume

141K

High

1.00

P/E Ratio

-1.13

52-wk high

2.40

Low

0.95

Div yield

N/A

52-wk low

0.73

Femasys Inc. has emphasized the potential of its FemaSeed product, positioning it as a cost-effective and lower-risk alternative to traditional assisted reproductive technologies. The company suggests that FemaSeed could become a preferred first-line therapeutic option for individuals seeking fertility treatments.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:03 pm

First Lady Jill Biden announced $100 million in federal funding for women's health R&D, aimed at addressing the historical underfunding in this area. The funding, provided by ARPA-H, seeks to encourage innovative research in women's health. Companies like Hologic Inc, Daré Bioscience Inc, Aspira Women’s Health Inc, Organon Inc., and Femasys Inc, which are involved in women's health diagnostics and treatments, could potentially benefit from this initiative.

Portfolio Pulse from Vandana Singh

February 21, 2024 | 5:24 pm

In Monday's after-market session, several health care stocks showed significant movement. Trxade Health (MEDS) saw a notable increase of 105.3%, while Universe Pharmaceuticals (UPC) experienced a significant decrease of 27.6%. Other stocks such as Iovance Biotherapeutics (IOVA) and Virpax Pharmaceuticals (VRPX) also saw upward movements, whereas companies like Sientra (SIEN) and Femasys (FEMY) faced declines.

Portfolio Pulse from Benzinga Insights

February 19, 2024 | 9:30 pm

In Thursday's intraday session, notable movements were observed in the healthcare stock sector. Syra Health (SYRA) saw a significant rise of 479.7%, while NanoString Technologies (NSTG) also surged by 197.18%. On the downside, Tenax Therapeutics (TENX) experienced a sharp decline of 64.7%, and Yield10 Bioscience (YTEN) fell by 31.2%. These movements reflect a dynamic day in the healthcare stock market, with both substantial gains and losses.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 5:31 pm

The article reports on the performance of health care stocks during Wednesday's intraday session, highlighting significant gainers and losers. ThermoGenesis Holdings led the gainers with a 39.0% increase, while CytoMed Therapeutics experienced the largest decline at 29.3%. The report provides insights into the stock movements and market capitalization of these companies.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 5:31 pm

Femasys Inc. has started enrolling participants for the pivotal trial of FemBloc, its investigational product for permanent birth control. The trial aims to evaluate the safety and efficacy of FemBloc.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:05 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Reshape Lifesciences (RSLS) led the gainers with a 22.3% increase, while NextCure (NXTC) saw the largest drop among the losers, falling 19.3%. Other notable gainers included Esperion Therapeutics (ESPR), Femasys (FEMY), Bio-Path Holdings (BPTH), Codexis (CDXS), and Akso Health Group (AHG). On the losing side, Apellis Pharmaceuticals (APLS), Ocular Therapeutix (OCUL), Pasithea Therapeutics (KTTA), Monte Rosa Therapeutics (GLUE), and Assure Holdings (IONM) also saw their stock prices decline.

Portfolio Pulse from Benzinga Insights

December 14, 2023 | 1:07 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Telesis Bio (TBIO) saw a 32.5% increase, while vTv Therapeutics (VTVT) faced a sharp 96.8% decline. Other notable gainers include Femasys (FEMY), Medigus (MDGS), TC BioPharm (TCBP), Assembly Biosciences (ASMB), and PaxMedica (PXMD). On the losing side, Impel Pharmaceuticals (IMPL), Aethlon Medical (AEMD), Ikena Oncology (IKNA), Biophytis (BPTS), and Heart Test Laboratories (HSCS) saw declines ranging from 10.56% to 31.96%.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 1:06 pm

In Thursday's after-market session, several healthcare stocks experienced significant movements. Inspire Veterinary (IVP) led the gainers with a 26.6% increase, while Axcella Health (AXLA) saw the largest decline among the losers, dropping 25.3%. Other notable gainers included Telesis Bio (TBIO), Femasys (FEMY), Assembly Biosciences (ASMB), MyMD Pharmaceuticals (MYMD), and Mira Pharmaceuticals (MIRA). On the losing side, Impel Pharmaceuticals (IMPL), Cardio Diagnostics Hldgs (CDIO), Alaunos Therapeutics (TCRT), Seelos Therapeutics (SEEL), and Heart Test Laboratories (HSCS) also saw their stock prices fall.

Portfolio Pulse from Benzinga Insights

November 23, 2023 | 9:31 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Telesis Bio (TBIO) led the gainers with a 32.5% increase, while Impel Pharmaceuticals (IMPL) saw the largest decline among the losers, dropping 13.3%. Other notable movers included Femasys (FEMY), Axcella Health (AXLA), and Gyre Therapeutics (GYRE), which released its Q1 earnings report.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.